Legal12 Feb 2026, 08:28 am
Zydus Lifesciences Settles US Patent Litigation with Astellas, to Pay USD 120 Million
AI Summary
Zydus Lifesciences Ltd and its wholly owned subsidiary, Zydus Pharmaceuticals USA, Inc., have entered into a Settlement Agreement with Astellas, concluding all litigations relating to Myrbetriq® and Mirabegron. The agreement requires Zydus to pay Astellas an aggregate amount of USD 120 million and a prepaid per unit licensing fee on units of Zydus’ generic Mirabegron sold in the US from the date of the Settlement Agreement till September 2027. This development enables Zydus to continue marketing its generic Mirabegron in the US.
Key Highlights
- Zydus Lifesciences and Astellas have settled US patent litigation related to Myrbetriq® and Mirabegron.
- Zydus to pay Astellas USD 120 million as part of the settlement.
- A prepaid per unit licensing fee will be paid by Zydus on units of its generic Mirabegron sold in the US from the date of the Settlement Agreement till September 2027.
- The settlement concludes all litigations between Astellas and Zydus relating to Myrbetriq® and Mirabegron.
- Zydus can continue marketing its generic Mirabegron in the US as a result of the settlement.